Feed 4519.T
45

Chugai Pharmaceutical Co., Ltd. 4519.T JPX · Healthcare · Japan

¥7,271.00 +0.90% +¥65.00

Summary

78 / 100 · Bulios Score

What speaks for it

  • Out of every 100 JPY of revenue, 36 JPY is left as net profit.
  • It earns 22 JPY a year on every 100 JPY of invested capital.
  • It holds more cash than debt: ¥382.3B against ¥16.1B.
  • The share price is below the Bulios Fair Price.

What to watch

None of the indicators we track raises a caution right now.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today ¥7,271

By our assumptions the business is worth more than its shares cost today.

P/E today 23.5 4.4% lower
5-year average P/E 24.6
P/E today 23.5
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 23.5 JPY for 1 JPY of yearly profit. Over the last five years it was 24.6 JPY on average.

Valuation in detail

Is it growing?

Slowly

Revenue (JPY)

Diluted EPS (JPY)

  • Analyst estimate

Revenue grew by 9.8% a year over 5 years. Over the last 3 years it fell by 0.1% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share grew by 5.0% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 JPY of revenue goes

Net profit, industry median (Drug Manufacturers - General) 15 JPY

Out of every 100 JPY of revenue, 36 JPY is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, at risk
Yield
0.92%
Paid out of profit
22%

You receive ¥66.00 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy